EGFR and non-small cell lung carcinoma: However, in patients with EGFR-mutant non-small cell lung cancer (NSCLC), the clinical benefits were not achieved when PD-L1 inhibitor durvalumab was combined with epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) osimertinib, and the combination only incurred more adverse events.